Short Interest in Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) Rises By 215.5%

Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totalling 50,800 shares, an increase of 215.5% from the November 30th total of 16,100 shares. Currently, 6.0% of the company’s stock are short sold. Based on an average trading volume of 200,500 shares, the days-to-cover ratio is currently 0.3 days.

Lipella Pharmaceuticals Stock Performance

LIPO traded up $0.16 during midday trading on Thursday, reaching $3.32. 166,281 shares of the company were exchanged, compared to its average volume of 166,970. Lipella Pharmaceuticals has a one year low of $2.21 and a one year high of $12.00. The company’s fifty day moving average price is $2.95 and its 200 day moving average price is $3.58. The company has a market cap of $4.01 million, a price-to-earnings ratio of -0.78 and a beta of 0.38.

Lipella Pharmaceuticals Company Profile

Lipella Pharmaceuticals Inc, a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD).